(ChemotherapyAdvisor) – Tivantinib increases time to tumor progression (TTP) and survival in patients with Met-positive hepatocellular carcinoma (HCC), according to the results of a phase 2 study presented at the 2012 Association for Clinical Oncology. The abstract was entitled “Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic…
The investigators sought to understand the relationships between familial clustering of hepatocellular carcinoma (HCC), family history of liver cancer and the incidence of hepatitis.
Danish researchers have established a link between childhood obesity and hepatocellular carcinoma (HCC) in adults.
Loco-regional therapy with selective internal radiation therapy (SIRT) and sorafenib demonstrated good efficacy in patients with advanced hepatocellular carcinoma (HCC), especially those in Barcelona Clinic Liver Criteria (BCLC) stage B.
Transarterial chemoembolization (TACE) with sequential sorafenib delayed time to progression (TTP) of intermediate-stage hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection, a prospective randomized study concluded in The Oncologist online February 14.
This fact sheet informs patients on the causes, symptoms, and treatment options for liver cancer.
